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Abstract
Background and Purpose—Radiomics provides opportunities to quantify the tumor 
phenotype non-invasively by applying a large number of quantitative imaging features. This study 
evaluates computed-tomography (CT) radiomic features for their capability to predict distant 
metastasis (DM) for lung adenocarcinoma patients.
Material and Methods—We included two datasets: 98 patients for discovery and 84 for 
validation. The phenotype of the primary tumor was quantified on pre-treatment CT-scans using 
635 radiomic features. Univariate and multivariate analysis was performed to evaluate radiomics 
performance using the concordance index (CI).
Results—Thirty-five radiomic features were found to be prognostic (CI > 0.60, FDR < 5%) for 
DM and twelve for survival. It is noteworthy that tumor volume was only moderately prognostic 
for DM (CI=0.55, p-value=2.77 × 10−5) in the discovery cohort. A radiomic-signature had strong 
power for predicting DM in the independent validation dataset (CI=0.61, p-value=1.79 ×10−17). 
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Adding this radiomic-signature to a clinical model resulted in a significant improvement of 
predicting DM in the validation dataset (p-value=1.56 × 10−11).
Conclusions—Although only basic metrics are routinely quantified, this study shows that 
radiomic features capturing detailed information of the tumor phenotype can be used as a 
prognostic biomarker for clinically-relevant factors such as DM. Moreover, the radiomic-signature 
provided additional information to clinical data.
INTRODUCTION
Lung cancer is the most deadly cancer worldwide for both men and women[1]. Nonsmall 
cell lung cancer (NSCLC) is the most common type of lung cancer (85–90% of all lung 
cancers) and adenocarcinoma is the most common subtype (about 40% of all lung cancers) 
of NSCLC. Patients with locally advanced (stage II-III) lung adenocarcinomas are typically 
treated with combined modality therapy including chemotherapy with local therapy 
including radiation therapy and/or surgery, but overall survival remains low due to a high 
risk of local recurrence and distant metastasis (DM) after treatment. Despite the use of 
concurrent chemotherapy with local therapy, the incidence of DM after combined modality 
therapy is as high as 30–40% in prospective trials [2–4]. However, large randomized trials 
studying consolidation chemotherapy after concurrent chemotherapy and radiation therapy 
have not shown improvement in overall survival with additional chemotherapy[5, 6] likely 
because there was no selection of patients at the highest risk of DM. Therefore, developing 
better biomarkers to predict patients at highest risk for DM may help identify sub-groups 
who benefit from intensification of systemic therapy and is crucial for improving outcomes.
Due to recent technological advances in medical imaging it is possible to capture tumor 
phenotypic characteristics non-invasively. The most widely used imaging modality is 
Computed-Tomography (CT), which can quantify tissue density. In lung cancer, CT 
imaging is routinely used for patient management, including diagnosis, radiation treatment 
planning and surveillance.
Tumor phenotypic differences (e.g. shapes irregularity, infiltration, heterogeneity or 
necrosis) can be quantified in CT images using radiomic features. Radiomics [7–9] aims to 
provide a comprehensive quantification of the tumor phenotype by analyzing robustly [10–
12] a large set of quantitative data characterization algorithms . Biomarkers based on 
quantitative features have demonstrated strong prognostic performance across a range of 
cancer types and investigators have reported that these features are associated with clinical 
outcomes and underlying genomic patterns [13–26]. Radiomics has significant clinical 
potential, as it can be applied to routinely acquired medical imaging data at low costs.
In this manuscript we present a radiomic analysis to identify biomarkers of DM in patients 
treated with chemoradiation (chemoRT) for locally advanced lung adenocarcinoma. In a 
discovery dataset, we extracted 635 radiomics features to identify the optimal features for 
predicting metastasis. Only a limited number of features with high performance for 
predicting DM were tested in the independent validation dataset. We evaluated the ability of 
radiomic features to predict DM or overall survival, and how these features compare with 
basic metrics (e.g. volume, diameter) as prognostic factors [27–30].
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MATERIALS AND METHODS
Patient characteristics
This study is an Institutional Review Board-approved analysis of CT for treatment 
simulation from North-American NSCLC patients receiving chemoRT at our institution 
from 2001 to 2013. We limited the patient population to pathologically-confirmed lung 
adenocarcinoma with locally advanced disease (overall stage II-III)[30]. Patients with 
surgery or chemotherapy before the scheduled radiation therapy planning CT date were 
excluded from the study. Patients treated before July 2009 were included in the discovery 
Dataset1 (n=98), and after July 2009 in an independent validation Dataset2 (n=84). In total 
182 patients were included in our analysis.
Clinical endpoints
Patients were followed up every three to six months after treatment, and surveillance chest 
CT scans with contrast (unless patient’s contraindication, e.g. allergy or renal dysfunction) 
were performed to assess treatment response or tumor progression based on US national 
guidelines (NCCN). The primary endpoint of this study was distant metastasis (DM), which 
was defined as progression of disease to other organs as assessed in surveillance scans, and 
time to DM was defined as time from start of radiation to date of DM or censoring (date of 
last scan). Overall survival was analyzed as a secondary endpoint, and was defined as the 
time between the start of radiation treatment and last day of follow up or date of death.
Clinical variables
The conventional clinical prognostic factors (CPFs) used for this study included tumor grade 
(1-Well differentiated, 2-Moderately differentiated, 3-Poorly differentiated and 4-Not 
available), Eastern Cooperative Oncology Group (ECOG) performance status (PS)[31], 
TNM stage per the American Joint Committee on Cancer (AJCC) staging system (7th 
edition)[30]; CT-based measurements commonly utilized in the clinic (e.g. tumor volume 
and maximal tumor diameter measured on single axial slice), and treatment characteristics. 
Sub-group analyses of clinical variables were performed (e.g. overall stage II vs IIIA vs 
IIIB) and can be found in Table S1 (Supplement II.1).
CT acquisition and segmentation
Planning CT was performed according to standard clinical scanning protocols at our 
institution with a GE “LightSpeed” CT scanner (GE Medical System, Milwaukee, WI, 
USA). The most common pixel spacing was (0.93mm, 0.93mm, 2.5mm) for CT. The 
primary lung tumor was delineated manually on Eclipse (Varian Medical System, Palo Alto, 
CA, USA). It was first contoured in the abdomen window to identify the boundaries with the 
chest wall or other soft tissues, then in the lung window to capture the maximum extent in 
the lung parenchyma. All contours were reviewed by an experienced radiation oncologist 
(R.H.M).
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Radiomic features extraction
Radiomic features have the capacity to capture tumor phenotype differences by examining a 
large set of quantitative features (Figure 1). The feature extraction was performed in 
MATLAB 2013b (Mathworks, Natick, MA, USA) using an in-house developed toolbox 
running on the Computational Environment for Radiotherapy Research (CERR)[32]. 
DICOMs files (CT images + tumor contours) were imported into CERR to extract the 
radiomic features. The radiomic features set included is described in detail in the 
Supplement I.
Feature selection
Feature selection for the radiomic signature was performed with the minimum redundancy 
maximum relevance (mRMR) algorithm implemented in the mRMRe[33] package version 
2.0.4 in R. The mRMR algorithm is an entropy based feature selection method, which starts 
by calculating the mutual information (MI) between a set of features and an outcome 
variable. MRMR ranks the input features by maximizing the MI with respect to outcome and 
minimizing the average MI of higher ranked features. Here, survival objects as implemented 
in R with “Survcomp” package[34] were used as outcome to select complementary features 
with respect to DM or survival.
Among available clinical covariates, those with p < 0.1 on univariate analysis of DM using a 
Log-Rank test were included into a multivariate clinical prognostic model.
Data analysis
Univariate and multivariate analyses were performed for this study. All analysis were 
performed on Dataset1, leaving Dataset2 as an independent validation cohort for evaluating 
the radiomic signature.
Statistical analysis was conducted using the survcomp[34] package version 1.12 and 
rmeta[35] package version 2.16 in Bioconductor[36]. Prognostic performances were 
evaluated by the concordance index[37] (CI), which is the probability that among two 
randomly drawn samples, the sample with the higher risk value has also the higher chance of 
experiencing an event (e.g. death or development of DM). CIs were either directly computed 
for continuous variables or on the predictions of a univariate Cox model with clinical 
categorical variables. Kaplan-Meier and Log-Rank statistics were used to analyze the 
univariate discrimination of survival and DM groups by imaging features and clinical 
covariates. To build the multivariate radiomic signature for DM, Cox regression models 
were trained on Dataset1 for selected prognostic variables and the predictions by these 
models were validated on Dataset2. Features were incrementally added to the model 
according to the relevance rank calculated by mRMR[33]. Intermediate models were tested 
by repeated random sub-sampling cross validation with 1,000 iterations on Dataset1. Once 
the mean CI of the growing model dropped, the corresponding feature set was retained 
selected as the final model. Only this selected model was and validated on Dataset2. 
Significance of CIs was assessed by bootstrapping subsamples of size 100 with 100 
repetitions for A) true survival data and B) random permutations of survival data, and 
comparing the empirical distributions of A) and B) by an one-sided Wilcoxon signed rank 
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test. The same procedure was used to assess if a CI was higher than another CI. To correct 
for multiple comparisons, we additionally adjusted P-values by the false-discovery-rate 
(FDR) procedure according to Benjamini and Hochberg[38]. All statistical analysis was 
performed using the R software[39] version 3.0.2.
RESULTS
The majority of all patients were female (62.6%) and the median age at start of treatment 
was 64 years (range: 35–93 years). The median follow-up time was 23.7 months (range: 
1.8–119.2 months) and the median survival time was 24.7 months (range: 1.8–119.2 
months). The median time to distant metastasis (DM) was 13.4 months (range: 0.3–117.5 
months). Patient characteristics, clinical outcomes are shown in Table 1.
Time to DM was similar between Dataset1 and Dataset2 (p-value < 0.36), as for the 
numbers of DM (p-value < 0.45). However, survival (p-value < 0.005) and follow-up times 
(p-value < 0.007) were significantly different in Dataset1.
We investigated the association of radiomics data with DM and overall survival. In Figure 2 
the association of the imaging features with DM and survival in the discovery Dataset1 is 
shown. Of the complete radiomic features set (m=635), a total of 520 (81.88%) and 582 
(91.65%) features were significant from random (FDR < 5%) for DM and survival, 
respectively. A total of 445 radiomic features were significant for both DM and survival. A 
high linear relationship was observed (R2 =0.92, p-value < 2.7 × 10−243), for the features 
significant for both DM and survival. It is noteworthy that LoG features had the highest 
performance compared to the other features groups.
Among all features, thirty-five radiomics features were strongly prognostic (CI > 0.60 and 
FDR < 5%) for DM (Table S2 in the Supplement II.3). Twelve features were found 
prognostic for survival. Specific details on statistic values of these features can be found in 
Table S3 in Supplement II.3. Between these two top performing feature sets there were four 
common prognostic features for both DM and survival. All of them were LoG based features 
(3 entropy and 1 standard deviation).
We compared the top 15 features that had the highest CIs (Top15), with tumor volume and 
diameter (equivalent to basic metrics). The Top15 radiomic features had notably higher CIs 
compared to tumor volume and diameter (Figure 3.A).
We also investigated the association of CPFs with DM in our data set. Three clinical 
parameters appeared to be significant univariate prognostic factors: Overall Stage (CI=0.63, 
p-value < 6.78 × 10−14), Gender (CI=0.63, p-value < 2.35 × 10−11) and tumor grade 
(CI=0.61, p-value < 2.35 × 10−11). Clinical parameters, ranked by their CI are displayed in 
Figure 3.B. Overall stage and gender yielded a higher CI than the radiomic features, 
although their 95% confidence interval is wider compared to the radiomic features.
An mRMR based feature selection on all features on Dataset1 (n=98) was performed to 
reduce redundancy and select a potential set of complementary and prognostic features. 
From this new ranking, the 15 highest mRMR-ranked features were kept after feature 
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selection to build the radiomic signature. A multivariate Cox regression model to predict 
DM was developed. Features were iteratively added in order of high to low mRMR rank on 
Dataset1, and Dataset2 was used for independent validation. The combination that yielded 
the maximum CI on the discovery Dataset1 before dropping was defined as the optimal 
radiomic signature for predicting DM. This signature consists of three features: 1) Wavelet 
HHL – Skewness, 2) Gray-Level Co-occurrence Matrix – Cluster shade, and 3) LoG 5mm 
2D – Skewness. Cluster shade is a textural feature sensitive to tumor heterogeneities. 
Skewness is a first-order feature that measures the asymmetry of the histogram from the 
mean, which here is associated with two different filters LoG and Wavelet.
As a final step, we compared the radiomic signature to a clinical Cox regression model 
containing covariates that significantly discriminated between patients with and without DM 
in Dataset1 in univariate analysis. The final model contained overall stage and tumor grade. 
This clinical model showed moderate prognostic power when applied to Dataset2 with 
coefficients trained on Dataset1 (CI=0.57, p-value < 1.03 × 10−7). Combining the clinical 
and radiomic signature (trained on Dataset1) showed a significantly (p-value < 1.56 × 10−11) 
higher association with DM when applied to Dataset2 (CI=0.60, p-value < 3.57 × 10−16), 
compared to the clinical model. A median split of the patient prediction scores from 
applying the combined model on Dataset2 yielded a significant difference (p-value = 0.049) 
for metastasis-free probability estimates (Figure 4).
DISCUSSION
Medical imaging gives valuable information for diagnostic, treatment planning or 
surveillance of cancer patients. Routinely, basic metrics are extracted from these images to 
utilize as a prognostic factor [27–30], or to assess treatment response. However, there is 
much more tumor phenotypic information captured in these images. Radiomics are able to 
quantify tumor phenotypical differences from medical images by using a large set of 
imaging features that can be linked to clinical factors of the tumors. In this study we 
extracted 635 radiomic features from a total of 182 lung cancer patients treated with 
chemoRT to assess the ability of radiomic features as a prognostic biomarker for distant 
metastasis (DM), and we validated a radiomic-based signature on an independent validation 
dataset. Since DM remains a major cause of mortality in 30–40% of patients with locally 
advanced lung adenocarcinoma, early identification of patients at highest risk of developing 
DM would allow clinicians to adapt treatment such as incorporating consolidation 
chemotherapy to improve outcomes. Moreover, the theoretical benefit of consolidation 
chemotherapy has not been shown in large randomized studies to date. It is likely because 
there was no selection of patients at the highest risk of distant metastases (i.e. patients who 
were at low risk of distant metastases were included in these trials and would not need 
additional treatment). Future trial design to demonstrate benefits of consolidation 
chemotherapy will likely require stratification to identify those at the highest risk of distant 
metastases and may benefit most from additional treatment.
We observed strong individual correlations between clinical outcomes and quantitative 
imaging features. A large number of features were significant from random to predict DM 
(91%) and survival (82%) in univariate analysis after correction for multiple testing. 
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Moreover, a high linear correlation was found among those 445 features that were 
significant factors of both DM and survival (R2 =0.92, p-value < 2.7 × 10−243). This high 
linear correlation is expected as there is a high correlation between DM and survival (DM 
greatly impact patient survival, see Table S4 in Supplement II.4). Only a small number of 
features, 35 for DM and for 12 survival, were prognostic, as defined by a CI > 0.6 and FDR 
< 5%.
Although we tested a large number of features, to minimize any risk of over-fitting or bias, 
we performed a robust validation approach: all analysis steps, mRMR feature selection, and 
model fitting were performed on Dataset1 (n=98) and the results validated on an 
independent validation Dataset2 (n=84). With this approach we found a multivariate 
radiomic DM signature consisting of three features that yielded a high prognostic 
performance for DM in Dataset1 (CI=0.61). Combining the radiomics signature to clinical 
model predictors showed significant improvement (p-value < 1.56 × 10−11), compared to the 
clinical predictors alone.
A recent study from Fried et al.[22] investigated DM prediction for NSCLC patients. They 
found a significant model DM (P-value=0.005) using both texture features and CPFs. The 
model used consisted of eight parameters (two CPFs and six textures). In another study, 
Ganeshan et al.[15] applied textural analysis to find univariate prognostic factors for 
survival. They focused on two imaging features (uniformity, associated with two LoG filter). 
In our analysis, these features were significant from random but lowly ranked by their CI 
value (184th and 146th CI-ranked features in Dataset1). However, major differences in 
studies design and implementation made it difficult to compare them objectively. Fields et 
al.[22] used leave-one out cross validation to validate their model instead of an independent 
validation dataset. Ganeshan et al.[15] only used one CT image slice (presenting the largest 
cross section) to calculate their features when we used the whole primary tumor. Finally, 
both these studies have a smaller patient cohort, n=54[15] and n=91[22], and had mixed 
histology patients. Our analysis calculated the features from the complete 3D tumor volume, 
contained only a single histology of NSCLC (adenocarcinoma), and is based on larger 
cohorts (n=182) with an independent validation dataset for the radiomic signature.
A complementary point of the study was to compare basic metrics [27–29] to radiomic 
features as prognostic factors for DM. The first observation made was that Shape-Maximum 
diameter (in every direction x/y/z) is a better univariate prognostic factors than the maximal 
tumor diameter on an axial slice reported by a radiologist. The advantage of the radiomic 
shape features is that they can be automatically acquired, reproducible[10–12], and take into 
account the whole tumor volume, whereas clinically assessed tumor diameters are manually 
drawn on a CT slice and are therefore limited to one dimension of the tumor. Furthermore, 
shape or size-based features were not in the top ranked features in our study. Total tumor 
volume, has been associated with survival in stage I-III NSCLC patients treated with 
radiation therapy in a study from Etiz et al.[28], and a prior study from our institution by 
Alexander et al.[29] also demonstrated an association between primary tumor volume and 
overal survival, but not risk of distant metastasis. In our study, volume was ranked only the 
405th (CI=0.55) and 224th (CI=0.56) best univariate prognostic factor for DM and survival 
respectively in Dataset1. Thus, while basic metrics such as size and volume have historically 
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been used as used in the clinical setting because such data are easily acquired, radiomic 
shape and size measurements can provide stronger prognostic factors.
A short-coming of our study is the variability in CT acquisition and reconstruction 
parameters. Our dataset includes patients from 2001 to 2013. During this time period, the 
standard of care for CT acquisition has evolved, differences appeared between our cohorts 
for some factors (Table 1). However, despite this variability in the imaging data (evolution 
of hardware, progress in informatics), radiomics was able to detect a strong signal to predict 
DM despite a temporal split. Additionally, clinical outcomes are provided by one center, 
which makes it hard to evaluate the generalizability of outcomes to other institutions. 
However, in comparison with a recent study[20] investigating clinical outcomes from 
another center, patient characteristics or outcomes were comparable. Future work would 
therefore involve studying the DM signature in other histologies and in independent 
validation sets from other institutions, assessing its generalizability to all NSCLC.
In conclusion, this study demonstrated strong association between radiomic features and 
DM for patients with locally advanced adenocarcinoma; and presented an independently 
validated radiomics signature for DM. This signature would allow early identification of 
patients with locally advanced lung adenocarcinoma at risk of developing DM, allowing 
clinicians to individualize treatment (such as intensification of chemotherapy) to reduce the 
risk of DM and improve survival.
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Highlights
• Early prediction of patients that will develop distant metastasis (DM) is crucial 
for improving overall treatment and patient outcomes.
• This study demonstrated an association between radiomic features and DM for 
lung cancer patients.
• A combined signature with clinical and radiomic features was able to predict 
DM in an independent validation dataset.
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Figure 1. 
A) Differences between lung primary tumors with a same histology are apparent on 
CT images (3D model on the right and CT contours on the left). CT images of primary 
tumors contain critical information that can be used to predict outcomes or assess the RT 
treatment response. B) To quantify this information, a large set of features (m=635) is 
used to capture the tumor phenotype. It includes 1| intensity, 2| shape and 3| texture based 
features. Also, A| Laplacian of Gaussian (LoG) and B| Wavelet filtered features were 
investigated. C) The final step is to link radiomic information to clinical data.
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Figure 2. Univariate performances of prognostic features for Distant Metastasis (DM) and 
survival
Each point refers to the CI of a feature evaluating the power of feature to predict metastasis, 
respectively, survival. Colors refer to the type of feature. Features whose CI estimation was 
not significant (FDR < 5%) for both DM and survival are shown in gray. Overall, 445 of 
these pairs of CIs are considered to be significant estimates. Linear regression for all 
significant pairs of CIs yielded an R-squared value of 0.92 (F-test, p-value < 2.7e-243).
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Figure 3. 
A) Forest plot of the 15 best performing radiomic features for Distant Metastasis on 
univariate analysis (Dataset1, n=98). Radiomics equivalent of basic metrics (diameter and 
volume) was added for comparison. B) Forest plot of the clinical factors. The absolute C-
indices and their 95% confidence interval are shown.
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Figure 4. Kaplan Meier curves according to the combined model predicting score to predict 
metastasis-free probability in an independent dataset
A significant survival difference appears between patients with a high or low risk of Distant 
Metastasis (Dataset2, n=84, Log-Rank test, p-value < 0.049).
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Table 1
Patient characteristics and outcomes are reported for each datasets. For categorical variables, actual numbers 
are reported for each category (format A/B/C). Statistical comparison between dataset 1 and 2 was computed 
using Chi Square (categorical variables) or Wilcoxon rank sum test (continuous variables).
Overall dataset
(n=182)
Dataset 1 (n=98) Dataset 2
(n=84)
P-
value
Median (range) Median (range) Median (range)
Age [years] 64 (35–93) 62 (41–86) 65 (35–93) 0.63
Gender [F/M] 114(62.6%)/
68(37.4%)
66(67.3%)/
32(32.7%)
48(57.1%)/
36(42.9%)
0.29
Overall stage [IIA/IIB/IIIA/IIIB] 6/3/101/72 2/1/55/40 4/2/46/32 0.65
T-stage [T1a/T1b/T2a/T2b/T3/T4] 19/23/50/19/39/32 14/10/30/10/17/17 5/13/20/9/22/15 0.26
N-stage [N0/N1/N2/N3] 13/17/97/55 5/9/53/31 8/8/44/24 0.70
Performance status [0/1/2/3] 81/91/8/2 36/57/5/0 45/34/3/2 0.04
Tumor grade [1/2/3/X] 4/28/92/58 3/11/47/37 1/17/45/21 0.12
Follow-up [months] 23.7 (1.8–119.2) 28.9 (1.8–119.2) 19.5 (3.1–54.9) 0.007
Survival [months] 24.7 (1.8–119.2) 29.7 (1.8–119.2) 21.4 (3.4–54.9) 0.005
Time to distant metastasis [months] 13.4 (0.3–117.5) 13.6 (0.3–117.5) 13.3 (0.7–49.6) 0.36
Distant metastasis [No/Yes] 69(37.9%)/
113(62.1%)
34(34.7%)/
64(65.3%)
35 (41.7%)/
49(58.3%)
0.45
Radiation dose delivered
≤ 54/≤ 60/≤ 66/> 66 [Gray]
60(32.97%)/
30(16.48%)/
70(38.45%)/
22(12.1%)
28(28.57%)/
17(17.35%)/
33(33.67%)/
20(20.41%)
32(38.10%)/
13(15.48%)/
37(44.04%)/
2(2.38%)
0.002
Chemotherapy sequence
[concurrent/adjuvant/induction]
175/79/28 95/38/22 80/41/6 0.024
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